Seawolf Therapeutics

Biotech · Private

Immunology therapeutics targeting autoimmune and inflammatory diseases

seawolftx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
18
0 granted · 18 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1647GENERAL NUTRACEUTICAL TECHNOLOGY LLC——
1648Boston Immune Technologies And Therapeutics Inc.——
1649Respana Therapeutics, Inc——
1650Seawolf Therapeutics——
1651KARIS BIO USA, INC.——
1652Eureka Therapeutics, Inc.—$86M
1653ALPH TECHNOLOGIES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 18
  • Unsaturated Ionizable Lipids And Nanoparticle Compositions Thereofapplication
  • Nuclear Targeted DNA Delivery and Compositions for Use in Practicing the Sameapplication
  • Enhanced Nuclear Delivery Of Dna And Compositions For Use In Practicing The Sameapplication
  • Unsaturated Ionizable Lipids and Nanoparticle Compositions Thereofapplication
  • Enhanced Nuclear Delivery of DNA and Compositions for Use In Practicing the Sameapplication
  • Enhanced Nuclear Delivery of DNA and Compositions for Use In Practicing the Sameapplication
  • Ionizable Lipids And Lipid Nanoparticle Compositions For The Delivery Of Nucleic Acidsapplication
  • Nucleic Acid Payload Delivery Systems, Compositions, And Methodsapplication
  • Nuclear Targeted Dna Delivery And Compositions For Use In Practicing The Sameapplication
  • Novel Lipid Nanoparticle Compositions For The Delivery Of Nucleic Acidsapplication
  • Ionizable Lipids And Lipid Nanoparticle Compositions For The Delivery Of Nucleic Acidsapplication
  • Nucleic Acid Payload Delivery Systems, Compositions, and Methodsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.